AstraZeneca to strengthen therapy area franchise through acquisition of Takeda's respiratory business
- Details
- Category: AstraZeneca
AstraZeneca today announced that it has entered into a definitive agreement to acquire the core respiratory business of Takeda Pharmaceutical Company Limited ("Takeda"). The deal will include the expansion of rights to roflumilast (marketed as Daliresp in the US and Daxas in other countries), the only approved oral PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).
Amgen reacquires all product rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) from GSK in 48 countries
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia® (denosumab), XGEVA® (denosumab) and Vectibix® (panitumumab) in 48 countries in Asia, South America, Europe, Australia and other regions throughout the world.
Bristol-Myers Squibb and UCLA enter into a collaboration agreement
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that they have entered into a collaboration agreement with UCLA as part of Bristol-Myers Squibb's Immuno-Oncology Rare Population Malignancy (I-O RPM) research program in the U.S.
Abbott and UC San Francisco discover new virus is linked to hepatitis C
- Details
- Category: Abbott
Abbott and University of California San Francisco (UCSF) published research identifying a newly discovered human virus, known as human pegivirus 2 (HPgV-2), and proving it is found among some patients with hepatitis C (HCV).
AstraZeneca to harness power of the Secretome and develop next-generation biologics in collaboration with new Wallenberg Centre for Protein Research
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, today announced a three-year collaboration with the newly established Wallenberg Centre for Protein Research (WCPR). The collaboration aims to develop new technologies for biologics production and to identify new targets for disease research in the ground-breaking area of the Secretome
Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud
- Details
- Category: Novo Nordisk
Novo Nordisk and IBM Watson Health today announced that the two companies will work together to create diabetes solutions built on the Watson Health Cloud. The agreement combines Novo Nordisk's deep understanding of diabetes with IBM's leadership in cognitive computing.
Shire partners with CrowdMed to offer US employees an innovative digital crowdsourcing diagnostic service
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced an innovative partnership with CrowdMed, a Web-based technology that harnesses "the wisdom of crowds" to solve difficult medical cases online. Starting January 1, 2016, CrowdMed will be offered as a pilot to US Shire employees and covered dependents.
More Pharma News ...
- 300 million child-friendly antimalarial treatments supplied without profit by Novartis
- AstraZeneca and Voluntis to test companion mobile app in ovarian cancer studies with the US National Cancer Institute
- Daratumumab combined with standard treatment for multiple myeloma produced deep and durable responses in relapsed or refractory patients
- GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries
- Roche and Upsher-Smith announce license agreement to develop novel VAP-1 inhibitor
- Bristol-Myers Squibb Foundation marks World AIDS Day with grants totaling more than $3.5M
- Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)